Semaglutide (Zhongshan Wanhan)

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering, demonstrating the company’s ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making effective, affordable GLP-1s accessible to Canadians for whom cost has long been a barrier to treatment. Nearly two-thirds of Canadian adults are overweight or living with obesity, but cost has remained a significant barrier to access the treatment they need. As the market becomes more dynamic and prices fall across the GLP-1 landscape, more eligible patients are now able to find the treatment that works best for their lifestyle and budget. This launch reflects Hims & Hers' ability to rapidly identify opportunities to help customers in global markets access safe, affordable care. "Bringing generic semaglutide to Canada is a meaningful milestone, but it's also a signal of something larger: our conviction that the model we've built in the United States can and should serve customers around the world," said Mike Chi, Chief Operating Officer, Hims & Hers. "There are millions of people in markets around the world who are ready for more ways to find affordable, high-quality care. Our ability to enter a new market, build a locally credible program, deliver access to first-of-its-kind medical treatment, and generate real impact at scale is what sets us apart." "Generics have always played a critical role in expanding access to medicines that change lives,” said Dr. Sandy Van, Obesity Medicine Specialist and Chief Medical Officer, Hims & Hers Canada. “Today marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient. Every Canadian deserves access to the treatment that's right for them, regardless of what they can afford." Now through Hims & Hers, eligible customers in Canada will have access to personalised care plans that may include generic semaglutide or branded options, alongside unlimited and ongoing Care Team access and evidence-informed resources built around nutrition, movement, and sleep, all designed to support sustainable, lasting habits for long-term weight management. All Canadian customers are seen by Canadian providers who bring local clinical expertise and a deep understanding of the Canadian healthcare landscape. Generic semaglutide is authorized for sale by Health Canada for the management of Type 2 diabetes. It may be prescribed off-label for weight management in a licensed healthcare provider's sole clinical judgment. Hims & Hers Canada Inc. does not currently offer access to treatment services for Type 2 diabetes. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com. Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding Hims & Hers’ ability to expand internationally and serve customers around the globe, and any assumptions relating to the foregoing. These statements are based on management’s current expectations, but actual results may differ materially due to various factors. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties relating to our ability to successfully expand into new markets or specialties; our ability to launch new products or offerings on expected timelines or at all; expectations regarding market acceptance, user experience and customer retention; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; the impact of general economic, business, or financial conditions; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of May 20, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this press release.

A new Sunlight survey of 1,000 U.S. peptide users finds that gray-market buyers visit the ER at 3x the rate of all peptide users. Three in four of these buyers have told their doctor about their peptide use, but the doctor never sees what was bought on social media. KIRKLAND, Wash., May 21, 2026 /PRNewswire/ -- Sunlight.com, a leading telehealth platform expanding access to personalized metabolic health and weight management care, released the findings of its Peptide Gray Market Report, revealing a fast-growing population of U.S. adults buying injectable peptides outside the regulated pharmacy system. While GLP-1 weight-loss drugs like Ozempic have dominated peptide coverage, the survey of 1,000 U.S. peptide users finds that the broader peptide market includes a substantial gray-market segment with sharply worse outcomes. The headline finding: 45% of peptide users who bought their peptides from Telegram, WhatsApp, or social media sellers have visited the emergency room or urgent care for a peptide reaction. The rate across all peptide users is 16%, making social-media buyers nearly 3x more likely to land in the ER. Key Findings ER outcomes diverge by sourcing channel: Nearly half (45%) of peptide users who bought from Telegram, WhatsApp, or social media have visited the ER for a peptide reaction, compared to 1 in 6 (16%) across all peptide users. Disclosure isn't oversight: 3 in 4 (76%) of social-media buyers have told their doctor about their peptide use, but the doctor never sees what was bought online. The gray market is bigger than it looks: 1 in 7 (14.5%) of all peptide users have bought from Telegram, WhatsApp, or social media sellers. AI is filling the dosing gap: 3 in 4 (75.5%) of peptide users have asked ChatGPT or another AI tool for peptide dosing or mixing instructions. The knowledge gap: Peptide users without a doctor are 3x more likely not to know what they're injecting. The Gray Market Operates Alongside Clinical Care Most coverage of the peptide gray market has framed it as an underground population avoiding medicine. The survey data points the other direction. The peptide users most likely to land in the ER are not flying solo. They are people in active clinical care who layer non-prescription peptide purchases on top of their doctor's oversight. Among the social-media buyers in the survey, 3 in 4 (76%) had told their doctor about their peptide use. The clinical relationship was real. What was missing was visibility into what was being injected. Peptides bought through social-media channels bypass the doctor's prescription system. Many ship without the peptide name on the label, often under a "for research use only" framing the FDA has flagged as a legal loophole. The DEA has documented social media as a primary channel for unregulated drug sales, and NPR has recently reported on buyers in peptide enthusiast groups dealing directly with overseas factory representatives, paying by cryptocurrency and receiving shipments by mail. The pattern leaves clinical oversight doing half the work. The doctor sees the prescription. The doctor does not see what was bought outside the prescription system. That visibility gap is where the worst outcomes concentrate. Where Peptide Users Are Buying A doctor or licensed healthcare provider: 62% An online retailer or research chemical website: 30% A U.S. compounding pharmacy: 30% Telegram, WhatsApp, or a social media seller: 14.5% An overseas supplier (China, South Korea, etc.): 10% A friend or coworker: 6% The medical channels remain the largest single source. The gray-market segment is smaller in absolute share but accounts for a disproportionate share of adverse outcomes. AI Is Filling the Dosing Gap Most peptides bought outside the prescription system come without official dosing instructions, so users have turned to AI to figure out how much to take. AI use is not limited to people without a doctor. 78.8% of peptide users who told their doctor about their peptide use have also asked AI for dosing. "While the physician is supervising one layer of the patient's peptide use, the patient is self-managing other products through gray-market channels the physician has no visibility into. Disclosure does not equal oversight, and that creates a false sense of clinical coverage on both sides," said Dr. Angela Tran, board-certified physician in internal and obesity medicine and Chief Medical Advisor at Sunlight. "The gray-market products are not subject to a high tier of quality assurance, so the ER physician is often managing a contamination or sterility issue rather than a dosing error." For detailed insights on the Peptide Gray Market Report, access the full report at: Methodology The findings presented are based on a survey conducted by Sunlight using Pollfish in May 2026. The survey collected responses from 1,000 U.S. adults who use, have purchased, or are considering injectable or oral peptides, and examined peptide sourcing channels, ER and urgent care visits, AI use for dosing, and knowledge of specific peptide products. Outcome questions referenced in this report were asked of the 518 respondents who reported having used or purchased peptides. All respondents passed a survey-wide attention check, and data collection adhered to Pollfish's quality control standards. About Sunlight Sunlight.com is a telehealth platform focused on expanding access to personalized metabolic health and weight management care. Sunlight connects users with licensed medical providers who, when clinically appropriate, may prescribe peptides, NAD+, and compounded GLP-1s like compounded semaglutide and compounded tirzepatide. The platform combines provider oversight, ongoing support, and convenient home delivery to simplify what has traditionally been a fragmented and inaccessible healthcare journey. As part of its commitment to transparency, Sunlight publishes original survey research and editorial reporting on weight loss, metabolic health, GLP-1 access, and emerging trends in clinical care. Sunlight's research has been cited by national health and consumer outlets. The company's mission is to help people build healthier, more sustainable lives by making metabolic and weight care more accessible and easier to navigate. Users can check eligibility through Sunlight's quiz or learn more about Sunlight's NAD+ program. For more, visit Sunlight.com Sources: FDA on "research use only" framing for peptides: FDA Warning Letter to Summit Research Peptides (Dec 2024) DEA on social media as a drug-sales channel: DEA Social Media Drug Trafficking Threat Overview (2022) NPR on overseas peptide sourcing: "Chinese peptides" biohacking coverage (Jan 2026) SOURCE Sunlight 21% more press release views with Request a Demo